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THE NORDBADEN PROJECT FOR HEALTH CARE
UTILIZATION RESEARCH IN GERMANY
Schlander M, Schwarz O
Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany
With a population of 82.5m, Germany represents the largest
health care market in Europe. Yet, research into epidemiology,
resource utilization, and actual cost associated with speciﬁc dis-
orders has been hampered by the fragmentation of the national
health care system. OBJECTIVES: 1) To establish an integrated
claims database in the German region of Nordbaden, allowing
retrospective patient-based analyses; 2) to evaluate how repre-
sentative the selected sample may be considered for Germany as
a whole; and 3) to assess its potential by determining adminis-
trative prevalence rates of ADHD. METHODS: The complete
claims database of the ofﬁcial physicians’ organization of Nord-
baden (KVNB) in South-Western Germany for the 4 quarters of
2003 was ﬁrst coded to protect the privacy of patients and physi-
cians, and subsequently integrated and restructured according to
patient pseudonyms, as to allow patient and disease speciﬁc
cross-sectional analyses. Sociodemographic and health care
related characteristics of the sample population were compared
with data for West Germany, East Germany, and Germany as a
whole. One-year prevalence rates were determined for attention-
deﬁcit/hyperactivity disorder (ADHD). RESULTS: Claims data
for 2.238m persons insured by the SHI (82.2% of the regional
population; cf. Germany: 70.4m or 85.3% SHI insured) were
available, representing—as judged by key sociodemographic and
medical indicators (which will be presented)—the German SHI
insured population. ADHD (hyperkinetic disorder: ICD-10,
F90.0, F90.1) prevalence rates were: age 0–6: 1.26% (boys:
1.72%, girls: 0.77%), age 7–12: 4.97% (boys: 7.15%, girls:
2.66%), age 13–19: 1.31% (males: 1.91%, females: 0.60%), and
adults: 0.04% (males: 0.04%, females: 0.03%). CONCLU-
SIONS: Especially when combined with data from regional hos-
pitals and sick funds, databases like the “Nordbaden Project”
will provide a valuable tool for studies of real-world health care
utilization and direct medical costs associated with deﬁned
medical conditions. Speciﬁc ﬁndings on ADHD will be discussed
in light of international epidemiological data.
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ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN
ADULTS: SF-6D UTILITIES FROM SF-36 SCORES IN A
RANDOMISED TRIAL OF ATOMOXETINE
Laing A,Aristides M
M-TAG, A division of IMS Health Economics and Outcomes
Research, London, London, UK
OBJECTIVES: To derive utilities for adults with ADHD from a
randomised trial of atomoxetine 40mg BID versus 80mg QD
(Adler et al., 2004). These patients are largely untreated and
there are few therapy alternatives. METHODS: Medical
Outcome Study Short Form-36 (SF-36) scores are converted into
a Quality Adjusted Life Year (QALY) value for key health states;
responder and non-responders without/with adverse event
(grouping deﬁned as per clinical trial). The method for conver-
sion is in accordance with that previously published (Brazier 
et al. 1998, 2004). A total of 218 clinical trial participants were
followed for 13 weeks. Pre-treatment utility data of all patients
is analysed to assess baseline utility values and is compared with
end of trial period. Missing data were addressed according to
ﬁve criteria. RESULTS: Mean and median results for utility
values for responder and non-responder groups produced 
consistent and sensible results (mean results presented unless
stated). Baseline utility was 0.634 and was consistent with non-
responder score at end of trial (0.630), as per expectation.
Responders had utility scores of 0.682 and 0.671, without/with
adverse events, respectively. All responders (i.e. regardless of
adverse event status) had a score of 0.678. The average gain in
utility at end of trial comparing non-responders with all respon-
ders was 0.048. Median results increased the utility gain to 0.08.
CONCLUSIONS: This analysis provided results that were ratio-
nal and consistent with efﬁcacy and safety ﬁndings with atom-
oxetine in the treatment of adults with ADHD. Improved utility
can be expected with treatment (0.048 to 0.08) and these data
can be used to populate an appropriate cost-utility analysis.
Conversion of SF-36 data to SF-6D values was informative and
consistent.
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DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF
QUETIAPINE IN COMBINATION THERAPY IN THE
MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
Klok RM1,Al Hadithy AF1,Van Schayk NP2,Antonisse AJ2,
Brouwers JR1, Postma MJ1
1University of Groningen, Groningen, Groningen,The Netherlands;
2AstraZeneca BV, Zoetermeer, Zuid Holland,The Netherlands
OBJECTIVES: To estimate the cost-effectiveness of quetiapine in
combination therapy compared to current combination therapies
in the treatment of acute mania in bipolar I disorder using a dis-
crete event model. METHODS: A discrete event simulation
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